Preveceutical begins trading on Frankfurt exchange
2017-08-01 09:43 ET - News Release
Mr. Stephen Van Deventer reports
PREVECEUTICALA MEDICAL INC. BEGINS TRADING ON THE FRANKFURT STOCK EXCHANGE
Preveceutical Medical Inc. has listed its common shares for trading on the Frankfurt Stock Exchange (FSE) under the symbol 18H. The Company's common shares now trade concurrently on the FSE and on the Canadian Securities Exchange (CSE) under the symbol "PREV."
The Frankfurt Stock Exchange is one of the world's largest, behind only the Nasdaq and NYSE, organized exchange-trading markets in terms of turnover and dealings in securities. The electronic trading platform of the FSE, XETRA, has made it the world's second-largest fully electronic cash market with direct linkage to all other major European financial hubs. Listing on the FSE will help increase PreveCeutical's trading liquidity and facilitate investment in the Company by European investors across the Frankfurt listing's major financial hubs like Switzerland, Luxembourg,
Lichtenstein, Monaco among others.
PreveCeutical's Chairman and CEO, Mr. Stephen Van Deventer commented, "We are pleased to have the Company listed on the Frankfurt Stock Exchange. Obtaining this listing will give PreveCeutical exposure to a much larger potential investor base and provide increased access to the European capital markets."
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. (CSE:PREV) is a biomedical company that coined the platform for preventive health sciences. PreveCeutical's innovative research and development department advances organic and Nature Identical products for both prevention and curative therapies.
The Company currently has one product available for sale, the CELLB9trademark Immune System Booster. CELLB9trademark is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. The active potentiated ingredients in the Blue Scorpion venom appear to support health at a deep cellular level, having been used for many years and in over 40 countries. The solution is colourless and odourless and can be administered orally.
We seek Safe Harbor.